A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing

Lamb, J. et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).

Hu, G. & Agarwal, P. Human disease-drug network based on genomic expression profiles. PLoS ONE https://doi.org/10.1371/journal.pone.0006536 (2009).

Dudley, J. T., Deshpande, T. & Butte, A. J. Exploiting drug–disease relationships for computational drug repositioning. Brief. Bioinform. 12, 303–311 (2011).

Kosaka, T. et al. Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming. Cancer Sci. 104, 1017–1026 (2013).

Wei, G. et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10, 331–342 (2006).

Hassane, D. C. et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 111, 5654–5662 (2008).

Stegmaier, K. et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat. Genet. 36, 257–263 (2004).

Lamb, J. The connectivity map: a new tool for biomedical research. Nat. Rev. Cancer 7, 54–60 (2007).

Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437–1452 (2017).

Duan, Q. et al. L1000cds 2: LINCS L1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 1–12 (2016).

Iwata, M., Sawada, R., Iwata, H., Kotera, M. & Yamanishi, Y. Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale chemically-induced transcriptomics. Sci. Rep. 7, 40164 (2017).

Méndez-Lucio, O., Baillif, B., Clevert, D.-A., Rouquié, D. & Wichard, J. De novo generation of hit-like molecules from gene expression signatures using artificial intelligence. Nat. Commun. 11, 1–10 (2020).

Sterling, T. & Irwin, J. J. Zinc 15–ligand discovery for everyone. J. Chem. Inf. Model. 55, 2324–2337 (2015).

Troyanskaya, O. et al. Missing value estimation methods for dna microarrays. Bioinformatics 17, 520–525 (2001).

Bø, T. H., Dysvik, B. & Jonassen, I. Lsimpute: accurate estimation of missing values in microarray data with least squares methods. Nucl. Acids Res. 32, e34–e34 (2004).

Kim, H., Golub, G. H. & Park, H. Missing value estimation for dna microarray gene expression data: local least squares imputation. Bioinformatics 21, 187–198 (2005).

Cai, Z., Heydari, M. & Lin, G. Iterated local least squares microarray missing value imputation. J. Bioinform. Comput. Biol. 4, 935–957 (2006).

Oba, S. et al. A bayesian missing value estimation method for gene expression profile data. Bioinformatics 19, 2088–2096 (2003).

Ouyang, M., Welsh, W. J. & Georgopoulos, P. Gaussian mixture clustering and imputation of microarray data. Bioinformatics 20, 917–923 (2004).

Wang, X., Li, A., Jiang, Z. & Feng, H. Missing value estimation for DNA microarray gene expression data by support vector regression imputation and orthogonal coding scheme. BMC Bioinform. 7, 32 (2006).

Lagunin, A., Ivanov, S., Rudik, A., Filimonov, D. & Poroikov, V. Digep-pred: web service for in silico prediction of drug-induced gene expression profiles based on structural formula. Bioinformatics 29, 2062–2063 (2013).

Perros, I. et al. Polyadic regression and its application to chemogenomics. In Proc. 2017 SIAM International Conference on Data Mining 72–80 (SIAM, 2017).

Hodos, R. et al. Cell-specific prediction and application of drug-induced gene expression profiles. In Pac. Symp. Biocomput Vol. 23, 32–43 (World Scientific, 2018).

Iwata, M. et al. Predicting drug-induced transcriptome responses of a wide range of human cell lines by a novel tensor-train decomposition algorithm. Bioinformatics 35, i191–i199 (2019).

Pham, T.-H. pth1993/DeepCE: First Release of DeepCE (Zenodo, 2020); https://doi.org/10.5281/zenodo.3978774

Liu, C. et al. Compound signature detection on LINCS L1000 big data. Mol. Biosyst. 11, 714–722 (2015).

Li, Z., Li, J. & Yu, P. l1kdeconv: an R package for peak calling analysis with LINCS L1000 data. BMC Bioinformatics 18, 356 (2017).

Qiu, Y., Lu, T., Lim, H. & Xie, L. A Bayesian approach to accurate and robust signature detection on LINCS L1000 data. Bioinformatics 36, 2787–2795 (2020).

Szklarczyk, D. et al. String v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucl. Acids Res. 47, D607–D613 (2019).

Wishart, D. S. et al. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucl. Acids Res. 34, D668–D672 (2006).

Zhou, Z. et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883–890 (2020).

Blanco-Melo, D. et al. SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems. Cell 181, 1036–1045 (2020).

Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

Duvenaud, D. K. et al. Convolutional networks on graphs for learning molecular fingerprints. In Proc. 28th International Conferene on Advances in Neural Information Processing Systems 2224–2232 (NIPS, 2015).

Vaswani, A. et al. Attention is all you need. In Proc. 30th Interrnational Conference on Neural Information Processing Systems 5998–6008 (NIPS, 2017).

Kotlyar, M., Fuhrman, S., Ableson, A. & Somogyi, R. Spearman correlation identifies statistically significant gene expression clusters in spinal cord development and injury. Neurochem. Res. 27, 1133–1140 (2002).

Allison, D. B., Page, G. P., Beasley, T. M. & Edwards, J. W. DNA Microarrays and Related Genomics Techniques: Design, Analysis, and Interpretation of Experiments (CRC, 2005).

Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

Mootha, V. K. et al. Pgc-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).

Ayed, M., Lim, H. & Xie, L. Biological representation of chemicals using latent target interaction profile. BMC Bioinform. 20, 674 (2019).

Cour, M., Ovize, M. & Argaud, L. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure? Crit. Care 24, 276 (2020).

Rudnicka, L. et al. Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern. J. Amer. Acad. Dermatol. 83, e151–e152 (2020).

Cure, E., Kucuk, A. & Cure, M. C. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). Rheumatol. Int. 40, 1177–1179 (2020).

Kemmner, S., Guba, M. O., Schönermarck, U., Stangl, M. & Fischereder, M. Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection. Kidney Int. 98, 507–508 (2020).

Hage, R., Steinack, C. & Schuurmans, M. M. Calcineurin inhibitors revisited: a new paradigm for COVID-19? Brazil. J. Infect. Dis. 24, 365–365 (2020).

Cavagna, L. et al. Calcineurin inhibitor-based immunosuppression and COVID-19: results from a multidisciplinary cohort of patients in northern Italy. Microorganisms 8, 977 (2020).

Softic, L. et al. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor alisporivir (Debio 025). Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.00876-20 (2020).

Syed, Y. Y. Ceftobiprole medocaril: a review of its use in patients with hospital-or community-acquired pneumonia. Drugs 74, 1523–1542 (2014).

Mevada, V. et al. Drug repurposing of approved drugs elbasvir, ledipasvir, paritaprevir, velpatasvir, antrafenine and ergotamine for combating COVID19. Preprint at https://doi.org/10.26434/chemrxiv.12115251.v2 (2020).

Wang, J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J. Chem. Inf. Model. 6, 3277–3286 (2020).

Shah, B., Modi, P. & Sagar, S. R. In silico studies on therapeutic agents for COVID-19: drug repurposing approach. Life Sci. 252, 117652 (2020).

Zhavoronkov, A. et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat. Biotechnol. 37, 1038–1040 (2019).